HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nicolin, A. Articles by Goldin, A. Search for Related Content PubMed Articles by Nicolin, A. Articles by Goldin, A.

Immunologic Cross-Reactivity of Antigen(s) Induced by Drug Treatment in Two Leukemic Sublines¹

From the Institute of Pharmacology, School of Medicine, Via Vanvitelli 32, Milan 20129, Italy and the National Cancer Institute, Bethesda, Maryland 20014

Abstract

Previous studies have demonstrated that new antigenic specificities, not detectable on parental cells, can be induced by in vivo treatment of murine leukemic cells with anti-neoplastic agents.

The immunologic properties of leukemic cells altered by treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) were investigated further. Immunologic cross-reactivity between two DIC-treated leukemic sublines has been demonstrated by cell-mediated immunity in vitro and by active or adoptive immunity in vivo. Rabbit antiserum to DIC-treated sublines absorbed with the parental cells showed residual activity against the DIC-sublines that was specifically inhibited by further absorption with DIC-cells.

Footnotes

¹ This work was supported in part by Contract N 74.00237.06 from Consiglio Nazionale delle Ricerche, Rome and Serpero Foundation, Milan.

² Address correspondence to: Dr. Abraham Goldin, Drug Research and Development Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20014.